AUGMENTIN XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Augmentin Xr, and when can generic versions of Augmentin Xr launch?
Augmentin Xr is a drug marketed by Us Antibiotics and is included in one NDA.
The generic ingredient in AUGMENTIN XR is amoxicillin; clavulanate potassium. There are forty-six drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Augmentin Xr
A generic version of AUGMENTIN XR was approved as amoxicillin; clavulanate potassium by SANDOZ on March 14th, 2002.
Summary for AUGMENTIN XR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 15 |
| Clinical Trials: | 74 |
| Patent Applications: | 814 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AUGMENTIN XR |
| DailyMed Link: | AUGMENTIN XR at DailyMed |
Recent Clinical Trials for AUGMENTIN XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital, Limoges | Phase 2 |
| Cairo University | Early Phase 1 |
| Western Sydney Local Health District | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for AUGMENTIN XR
Paragraph IV (Patent) Challenges for AUGMENTIN XR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AUGMENTIN XR | Extended-release Tablets | amoxicillin; clavulanate potassium | 1000 mg/62.5 mg | 050785 | 1 | 2009-01-21 |
US Patents and Regulatory Information for AUGMENTIN XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AUGMENTIN XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AUGMENTIN XR
See the table below for patents covering AUGMENTIN XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 200000133 | ⤷ Try a Trial | |
| Austria | 4327 | ⤷ Try a Trial | |
| South Africa | 200108321 | Novel method of treatment. | ⤷ Try a Trial |
| China | 1225246 | ⤷ Try a Trial | |
| Australia | 771639 | ⤷ Try a Trial | |
| New Zealand | 514574 | Novel method of treatment | ⤷ Try a Trial |
| Norway | 329694 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
